OUR FACILITIES
cGMP Manufacturing
(Hwaseong Plant)
Built for scale: Delivering commercial scale manufacturing with consistency and reliability.
Established in 2016 in response to growing customer demand, Yuhan’s Hwaseong Plant is mainly built for large-scale commercial manufacturing. The facility has successfully supported multiple commercial campaigns, demonstrating proven scalability and reliability.
We continue to expand this foundation by investing in advanced technologies and strengthening our continuous manufacturing capabilities.
  • icon
    Total Site Area
    36,526 ㎡
  • icon
    Total Reactor Capacity
    532,650 L
  • icon
    Established
    2016
  • icon
    Containment Level
    OEB 4 (~1 µg/m³)
OUR FACILITY
Interactive Site Map
Explore the Hwaseong plant, a key hub in Yuhan’s global CDMO operations.
Hover over each building to learn more about its function and capabilities.
icon Hover over a building to view details.
Production Bldg. HA
  • icon
    Capacity
    237.35㎥
    (Including 1.35 ㎥ of Pilot)
Production Bldg. HB
  • icon
    Capacity
    295.3㎥
    (Including 3.3 ㎥ of Pilot)
QC/QA/Maintenance/ Administration
Raw Material Warehouse
(Under Construction)
Production Bldg. HC
(Under Construction)
Solvent Tank Farm
General Warehouse
YUHAN CDMO
Plant Overview
From development to manufacturing, we bring experience, rigor, and collaboration to every step.
  • icon
    01 / Technology
    Hydrogenation and Flow Chemistry
    The Hwaseong plant is equipped for high-pressure catalytic hydrogenation and continuous flow chemistry, with both packed bed and plug flow reactors on site. Both capabilities are available from process development through clinical and commercial manufacturing.
  • icon
    02 / Supply
    Consistent, High-Quality Manufacturing
    Hwaseong has been inspected by the US FDA, Korea MFDS, and Brazil ANVISA, and supplies GMP intermediates and APIs to regulated markets.
  • icon
    03 / Capacity
    Pilot to Commercial Scale
    The plant operates both pilot-scale and large-scale reactors, allowing programs to move from clinical supply to commercial production at the same site.
  • icon
    04 / Expansion
    Continued Expansion
    Capacity at Hwaseong continues to grow, with the upcoming HC production building adding further manufacturing capacity.
TRUSTED WORLDWIDE
Regulatory Track Records
Inspected by the FDA, MFDS, and ANVISA since 2016 with no major observation.
  • icon
    US FDA
    FOOD AND DRUG
    ADMINISTRATION
    Since 2017
  • icon
    Brazil ANVISA
    BRAZILIAN HEALTH
    REGULATORY AGENCY
    Since 2024
  • icon
    Korea MFDS
    MINISTRY OF FOOD
    AND DRUG SAFETY
    Since 2016
OUR LOCATION
Location
Strategically located 25km (16 miles) from our Ansan Plant.